EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of N-Hydroxypyridinedione-Based Inhibitors of HBV RNase H: Design, Synthesis, and Extended SAR Studies

Dea Chotzalli iD, Vasiliki Pardali, Holly M Walden, Dimitrios Perivolaris, Dimitrios Moianos iD, Maria Makri, Antonios Drakopoulos iD, Erofili Giannakopoulou iD, Razia Tajwar, Molly E Woodson, John E Tavis iD, Grigoris Zoidis iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262010239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Dea Chotzalli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimio…. Hauptthemen laut MEDLINE: Hepatitis B virus, Antiviral Agents, Ribonuclease H, Enzyme Inhibitors. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B Virus (HBV) continues to pose a significant global health challenge, with over 254 million chronic infections and current therapies being non-curative, necessitating lifelong treatment. The HBV ribonuclease H (RNase H) is essential during HBV reverse transcription by cleaving the viral pregenomic RNA after it has been copied into the (−) polarity DNA strand, enabling the viral polymerase to synthesize the (+) DNA strand. Although RNase H inhibition terminates viral replication and thus viral infectiveness, its targeting as an HBV treatment is unexploited. Its catalytic site contains four carboxylates that bind to two Mg2+ ions essential for RNA hydrolysis. As part of our ongoing research on RNase H inhibitors, we developed 23 novel N-hydroxypyridinedione (HPD) analogues. Specifically, 17 HPD imines, 4 HPD oximes, 1 2,6-diamino-4-((substituted)oxy)pyrimidine 1-oxide derivative, and 1 barbituric acid analogue were designed, synthesized, and tested for their anti-HBV activity. The HPD derivatives could be docked in the RNase H active site to coordinate the two Mg2+ ions and effectively inhibited viral replication in cellular assays. The 50% effective concentration (EC50) values of these HPD compounds ranged from 0.5 to 73 μM, while the 50% cytotoxic concentration (CC50) values ranged from 15 to 100 μM, resulting in selectivity indexes (SIs) up to 112. Furthermore, the novel HPD derivatives exhibited favourable pharmacokinetic-relevant characteristics, including high cellular permeability, good aqueous solubility, and overall drug-like properties. These findings indicate that HPD imines and oximes possess substantial antiviral potency and selectivity against HBV, underscoring the potential of the HPD scaffold as a promising framework for the development of next-generation anti-HBV agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusAntiviral AgentsRibonuclease HEnzyme InhibitorsHumansVirus ReplicationStructure-Activity RelationshipDrug DesignMolecular Docking SimulationDrug Discovery

Stichwörter der Autor:innen

Hepatitis B virusN-HydroxypyridinedionesRibonuclease Hanti-HBV agentsiminesoximesstructure-activity relationships

Substanzen

Antiviral AgentsRibonuclease HEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.
  • Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA.
  • Saint Louis University Institute for Drug and Biotherapeutic Innovation, Saint Louis University, Saint Louis, MO 63104, USA.
  • Department of Chemistry and Molecular Biology, University of Gothenburg, 41296 Göteborg, Sweden.

ORCID-Profile: Dea Chotzalli, Dimitrios Moianos, Antonios Drakopoulos, Erofili Giannakopoulou, John E Tavis, Grigoris Zoidis

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement
  • USA National Institutes of Health
  • European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curi

Zitieren

APA

Chotzalli, D., Pardali, V., Walden, H. M., Perivolaris, D., Moianos, D., Makri, M., Drakopoulos, A., Giannakopoulou, E., Tajwar, R., Woodson, M. E., Tavis, J. E., & Zoidis, G. (2025). Discovery of N-Hydroxypyridinedione-Based Inhibitors of HBV RNase H: Design, Synthesis, and Extended SAR Studies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010239

Vancouver

Chotzalli D, Pardali V, Walden HM, Perivolaris D, Moianos D, Makri M, et al. Discovery of N-Hydroxypyridinedione-Based Inhibitors of HBV RNase H: Design, Synthesis, and Extended SAR Studies. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010239

BibTeX
@article{Chotzalli2025,
  author = {Chotzalli, Dea and Pardali, Vasiliki and Walden, Holly M and Perivolaris, Dimitrios and Moianos, Dimitrios and Makri, Maria and Drakopoulos, Antonios and Giannakopoulou, Erofili and Tajwar, Razia and Woodson, Molly E and Tavis, John E and Zoidis, Grigoris},
  title = {Discovery of N-Hydroxypyridinedione-Based Inhibitors of HBV RNase H: Design, Synthesis, and Extended SAR Studies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262010239}
}
Kostenlos starten →